Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PSMB1 | P20618 | 3/20 | 0.39 |
| ▸ | PSMB5 | P28074 | 3/20 | 0.39 |
| ▸ | PSMB2 | P49721 | 2/20 | 0.39 |
| ▸ | SLC6A4 | P31645 | 4/20 | 0.37 |
| ▸ | SLC6A3 | Q01959 | 4/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.34 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.34 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.33 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14748856 | 0.87 | KDM4E (0.37) | PSMB1PSMB5PSMB2SLC6A4SLC6A3 | |
| SCHEMBL12123112 | 0.76 | PSMB1 (0.40) | PSMB1PSMB5PSMB2SLC6A4SLC6A3 | |
| SCHEMBL12123117 | 0.73 | PSMB1 (0.38) | PSMB1PSMB5PSMB2SLC6A4SLC6A3 | |
| SCHEMBL10196944 | 0.73 | PSMB1 (0.41) | PSMB1PSMB5SLC6A4SLC6A3KDM4E | |
| SCHEMBL12207087 | 0.71 | HSD17B10 (0.33) | HSD17B10 | |
| SCHEMBL14748857 | 0.71 | — | — | |
| SCHEMBL12233179 | 0.71 | HSD17B10 (0.33) | HSD17B10 | |
| SCHEMBL12123116 | 0.71 | PSMB1 (0.36) | PSMB1PSMB5PSMB2SLC6A4SLC6A3 | |
| SCHEMBL24856604 | 0.70 | ALDH1A1 (0.39) | PSMB1PSMB5PSMB2SLC6A4SLC6A3 | |
| SCHEMBL9081026 | 0.70 | PSMB1 (0.42) | PSMB1PSMB5PSMB2SLC6A4SLC6A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130060013-A1 | Compounds useful for treating neurodegenerative disorders | SATORI PHARMACEUTICALS, INC. (US) | 2013-03-07 | — | — | US | disclosed |
| US-20130060013-A1 | Compounds useful for treating neurodegenerative disorders | SATORI PHARMACEUTICALS, INC. (US) | 2013-03-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130060013-A1 | Compounds useful for treating neurodegenerative disorders | SNCA, HTT, CLN6 | PSMB1 3254/4885PSMB5 800/4885PSMB2 2467/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.